Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms

Reginster, Jean-Yves; Bruyère, Olivier; Cooper, Cyrus

doi:10.1136/annrheumdis-2017-212251

Cited by 16 publications

(16 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Only the prescription crystalline glucosamine sulfate (pCGS) is shown to deliver consistently high glucosamine bioavailability and plasma concentration in humans, which corresponds to demonstrated clinical efficacy [10][11][12]. Conversely, glucosamine hydrochloride and non-characterized glucosamine sulfate products are repeatedly demonstrated as ineffective in OA [12][13][14]. Similarly, only pharmaceutical-grade chondroitin sulfate (CS) has been evaluated for purity, content and physiochemical parameters [9], and clinical evidence supports only pharmaceuticalgrade CS [15].…”

Section: Sysadoasmentioning

confidence: 99%

Endorsement by Central European experts of the revised ESCEO algorithm for the management of knee osteoarthritis

et al. 2019

Self Cite

View full text Add to dashboard Cite

Osteoarthritis (OA) is characterized by deterioration of the joints and associated with considerable pain and disability. OA is a chronic disease that requires intervention with both non-pharmacological and pharmacological treatment modalities and, inevitably, disease progression may necessitate successive treatments throughout the course of the disease. There is increasing data on the shortfalls of current pharmacological treatment of OA, and safety concerns associated with analgesic therapy use in OA arising from increasing evidence of gastrointestinal, cardiovascular, hepatic and renal adverse events with paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs). Consequently, symptomatic slow-acting drugs for OA (SYSADOAs) may now be considered as a first-line treatment for knee OA, with a particular emphasis placed on the outstanding benefit: risk ratio of pharmaceutical-grade glucosamine and chondroitin sulfate formulations. In this short communication we review recent publications concerned with the safety of paracetamol, NSAIDs and SYSADOAs. Greater understanding of the benefits and limitations of current medications will lead to better disease management in OA. Furthermore, adherence to guideline recommendations across Europe and internationally, such as those from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), will promote evidence-based medicine and patient-centric care, ultimately leading to greater physician and patient satisfaction.

show abstract

Section: Sysadoasmentioning

confidence: 99%

Endorsement by Central European experts of the revised ESCEO algorithm for the management of knee osteoarthritis

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…During this reaction, chitin is deacetylated and depolymerized to glucosamine hydrochloride in the presence of hydrochloric acid solution . However, it was later reported that glucosamine hydrochloride was ineffective in the treatment of osteoarthritis mainly because of its pharmacokinetics limitations (Reginster et al, 2018). Glucosamine sulfate which is made from glucosamine hydrochloride by adding either potassium or sodium sulfate and co-crystallizing the resulting mixture was approved as a prescription drug in Europe and elsewhere (Mojarrad et al, 2007).…”

Section: Glucosamine and N-acetyl Glucosaminementioning

confidence: 99%

Utilization of marine by-products for the recovery of value-added products

Shahidi¹,

Varatharajan²,

Han³

et al. 2019

JFB

View full text Add to dashboard Cite

The world fisheries resources have exceeded 160 million tons in recent years. However, every year a considerable amount of total catch is discarded as by-catch or as processing leftovers, and that includes trimmings, fins, frames, heads, skin, viscera and among others. In addition, a large quantity of processing by-products is accumulated as shells of crustaceans and shellfish from marine bioprocessing plants. Recognition of the limited marine resources and the increasing environmental pollution has emphasized the need for better utilization of the by-products. Marine by-products contain valuable protein and lipid fractions, minerals, enzymes as well as many other components. The major fraction of by-products are used for feed production-in making fish meal/oil, but this has low profitability. However, there are many ways in which the fish and shellfish waste could be better utilized, including the production of novel food ingredients, nutraceuticals, pharmaceuticals, biomedical materials, fine chemicals, and other value-added products. In recent times, much research is conducted in order to explore the possible uses of different by-products. This contribution primarily covers the characteristics and utilization of the main ingredients such as protein, lipid, chitin and its derivatives, enzymes, carotenoids, and minerals originating from marine by-products.

show abstract

“…Целевая группа ESCEO выступает за дифференциацию микрокристаллического ГС (мГС) с другими препаратами глюкозамина. Долгосрочные клинические испытания и исследования в реальной жизни показывают, что мГС может задерживать комплексные структурные изменения, предполагая потенциальную выгоду за пределами контроля симптомов при использовании на ранних стадиях управления ОА коленного сустава [62].…”

Section: адекватное потребление калорий и белка -примени-unclassified

Chronic pain in older people: focus on sarcopenia

Наумов¹,

Мороз²,

Ховасова³

et al. 2019

Medicinskij sovet

View full text Add to dashboard Cite

Наумов Антон Вячеславовичд.м.н., профессор кафедры болезней старения ФДПО Федерального государственного бюджетного образовательного учреждения высшего образования «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова», заведующий лабораторией костно-мышечной системы Обособленного структурного подразделения «Российский геронтологический научно-клинический центр» Федерального государственного бюджетного образовательного учреждения высшего образования «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Министерства здравоохранения Российской Федерации; старший научный сотрудник Федерального центра координации деятельности субъектов Российской Федерации по развитию организации оказания медицинской помощи по профилю «гериатрия»; тел.:

show abstract

Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms

Cited by 16 publications

References 16 publications

Endorsement by Central European experts of the revised ESCEO algorithm for the management of knee osteoarthritis

Endorsement by Central European experts of the revised ESCEO algorithm for the management of knee osteoarthritis

Utilization of marine by-products for the recovery of value-added products

Chronic pain in older people: focus on sarcopenia

Contact Info

Product

Resources

About